ID Week

Li Tao, PhD, discusses early US uptake of twice-yearly lenacapavir, faster prescription-to-injection timelines, and how ACA coverage milestones tracked with zero cost sharing and HIV diagnoses.

David Altarac, MD, discusses 2025 SENTRY data, ESBL considerations in empiric therapy, and where ceftobiprole fits alongside ceftaroline in S aureus bacteremia.

Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.

Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.

Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.

Labcorp data presented at IDWeek 2026 show measles PCR testing nearly quadrupled and positivity rose sharply from April 2025 through March 2026, as clinicians shift toward guideline-recommended molecular testing amid ongoing US outbreaks.

In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.

David Altarac, MD, discusses the 2026 IDSA guidance, which prioritizes sulbactam-durlobactam plus a carbapenem for invasive carbapenem-resistant Acinetobacter infections.

Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.

Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.

Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.

Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.

Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.

In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.

Exploratory SCORPIO-PEP data presented at IDWeek 2026 show household contacts with breakthrough COVID-19 on ensitrelvir had lower peak viral RNA and fewer severe symptoms than placebo recipients.

Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.

MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.

Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.

Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.

Isavuconazole had a lower liver adverse event signal than voriconazole and posaconazole, while olorofim, manogepix, and rezafungin held activity against resistant molds.

Data being presented at IDWeek 2026 show zoliflodacin maintains high gonorrhea cure rates in patients co-infected with chlamydia. David Altarac, MD, discusses the therapy and the study being presented at the conference.

In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.

Oral pritelivir improved lesion healing and cut hospitalizations from 76% to 29.4% vs investigator's choice therapy in immunocompromised patients with refractory HSV.

Investigational cefiderocol-xeruborbactam inhibited 98.5% of carbapenem-nonsusceptible Acinetobacter and nearly all Enterobacterales in global surveillance data.

Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.

Nicholas Van Hise, PharmD, discusses a real world study, ROAR, showing that fecal microbiota, live-jslm (RBL), maintains strong efficacy and safety in preventing recurrent Clostridioides difficile infection (rCDI) in routine US clinical practice.

Jonathan Parr, MD, MPH, discusses his work in locating potential targets to develop a syphilis vaccine and the challenges associated with genomic diversity of subpopulations of the main pathogen, Treponema pallidum.

Shionogi has been identifying in vitro activity using its antibiotic, cefiderocol, against Gram-negative clinical isolates such as carbapenem-resistant Enterobacterales (CRE). Christine Slover, PharmD, offers some insights on the company’s analysis.

Timothy Jenkins, MD, talks about how these important tests are being overly used for respiratory and gastrointestinal presentations and strategies his institution, Denver Health, is employing to reduce testing to save costs and still continuing to achieve optimal treatment outcomes.

Kaylee Caniff, PharmD, BCIDP, provides insights on a study looking at how urban and rural healthcare settings differ in terms of prescribing.